Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hdac3tm1.1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Hdac3tm1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
|
|
|
cellular
|
• several markers of DNA damage are increased in MEFs at 72 h after adenoviral cre infection
• blocking progression through the cell cycle by serum starving cells reduces the amount of DNA damage detected
• sensitivity to DNA damage by ionizing radiation is also increased in adenoviral cre infected MEFs
|
|
• impaired cell cycle progression prior to metaphase in adenoviral cre infected MEFs
• viral cre infected cells display about a 2 h delay in moving from S phase through G2/M and re-entering G1
|
|
• by 120 h post adenoviral cre infection about 20 - 30% of MEFs are dying
|
|
• about a 2-fold reduction in BrdU positive MEFs after adenoviral cre infection
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hdac3tm1.1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Hdac3tm1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
liver/biliary system
|
• 2 weeks after the final pIpC injection liver size is increased about 2-fold
• gradual increase in hypertrophic hepatocytes with grainy cytoplasm following pIpC injections
|
|
• 2 weeks after the final pIpC injection liver weight is increased about 2-fold
|
|
• dramatic depletion of glycogen in hepatocytes after pIpC injections
|
|
• gradual increase in hypertrophic hepatocytes with grainy cytoplasm following pIpC injections
|
homeostasis/metabolism
growth/size/body
|
• 2 weeks after the final pIpC injection liver size is increased about 2-fold
• gradual increase in hypertrophic hepatocytes with grainy cytoplasm following pIpC injections
|
|
• 2 weeks after the final pIpC injection liver weight is increased about 2-fold
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hdac3tm1.1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Hdac3tm1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Tg(CAG-cre/Esr1*)5Amc mutation
(9 available)
|
|
|
cellular
|
• impaired cell cycle progression prior to metaphase in tamoxifen treated MEFs
|
|
• in MEFs following tamoxifen treatment
|
|
• several markers of DNA damage are increased in MEFs after tamoxifen treatment
|
homeostasis/metabolism
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hdac3tm1.1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Hdac3tm1Swh mutation
(0 available);
any
Hdac3 mutation
(31 available)
Speer6-ps1Tg(Alb-cre)21Mgn mutation
(6 available);
any
Speer6-ps1 mutation
(4 available)
|
|
|
mortality/aging
N |
• unlike homozygous null mice, mice with loss of expression in the liver after birth are viable
|
liver/biliary system
|
• at 6 - 8 weeks of age, but not at P17, the number of proliferating cells is increased
|
|
• by P28 livers are hypertrophic
|
|
• ratio of liver weight to body weight is increased to about 25 - 30% compared to about 5% in heterozygous mice
|
|
• dramatic depletion of glycogen in hepatocytes
|
|
• up to a 17-fold increase in triglyceride levels in the liver at P17
|
|
• cells with abnormal cytoplasm are apparent at P17
|
|
• accumulation of lipid droplets
• elevated triglyceride levels at P17
• treating mice with rapamycin reduces neutral lipid accumulation but does not alter the increase in liver size
|
homeostasis/metabolism
growth/size/body
|
• by P28 livers are hypertrophic
|
|
• ratio of liver weight to body weight is increased to about 25 - 30% compared to about 5% in heterozygous mice
|
adipose tissue
|
• visibly leaner with a substantial reduction in visceral adipose tissue by 6 - 8 weeks of age
|
cellular
|
• at 6 - 8 weeks of age, but not at P17, the number of proliferating cells is increased
|